Device Trial Radar · NCT07620548
Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
99
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
May 31, 2031
Study completion Nov 30, 2032
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma. Patients will be enrolled and randomized on a 2:1 ratio to either the experimental arm (LiTT + cemiplimab) or the control arm (LiTT + physician/s choice chemotherapy).
Conditions
- Glioblastoma
- Glioblastoma, IDH-wildtype
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
NeuroBlate® Laser Ablation Laser Interstitial Thermal TherapyDevice
LiTT, or magnetic resource imaging (MRI)-guided laser ablation, is a minimally invasive surgery approved for cytoreductive treatment of brain tumors. It employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MRI imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.
CemiplimabDrug
Cemiplimab is a programmed death receptor-1 (PD-1)-blocking antibody that is administered intravenously at 350mg over 30 minutes every 3 weeks on an outpatient basis.
ChemotherapyDrug
Adjuvant chemotherapy will be decided by the physician's choice of best fit by patient, including the agent(s), dosing, and schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) at Month 6 (PFS6)Time frame: Start of treatment through 6 months after start of treatment (month 6)
- Overall survival (OS) at Month 18 (OS18)Time frame: Start of treatment through 18 months after start of treatment (month 18)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.